Asthma is a chronic respiratory disease characterized by respiratory symptoms, airway inflammation, airway obstruction and airway hyper-responsiveness. Asthma is common and directly affects 10% of Australians, 1-5% of adults in Asia and 300 million people worldwide. It is a heterogeneous disorder with many clinical, molecular, biological and pathophysiological phenotypes. Current management strategies successfully treat the majority of patients with asthma who have access to them. However, there is a subset of an estimated 5-10% of patients with asthma who have severe disease and are disproportionately impacted by symptoms, exacerbations and overall illness burden. The care required for this relatively small proportion of patients is also significant and has a major impact on the healthcare system. A number of new therapies that hold promise for severe asthma are currently in clinical trials or are entering the Australian and international market. However, recognition of severe asthma in clinical practice is variable, and there is little consensus on the best models of care or how to integrate emerging and often costly therapies into current practice. In this article, we report on roundtable discussions held with severe asthma experts from around Australia, and make recommendations about approaches for better patient diagnosis and assessment. We assess current models of care for patient management and discuss how approaches may be optimized to improve patient outcomes. Finally, we propose mechanisms to assess new therapies and how to best integrate these approaches into future treatment.
INTRODUCTION
Severe asthma has high morbidity, excessive mortality and represents a disproportionate economic burden to the community. [1] [2] [3] [4] [5] There have been significant advances in the treatment of mild-to-moderate asthma, with corresponding improvements in health outcomes. However, severe asthma that is refractory to standard treatment remains a significant health problem and accounts for the majority of healthcare expenditure for asthma. 4, 6 Despite the impact and burden of this disease, it is an exciting time for severe asthma as we enter an era of personalized medicine, have a greater understanding of the underlying mechanisms 7, 8 and have access to promising new therapies (reviewed in Ref. 9 ). However, little consensus exists on how to optimize models of care and implement new therapies. The challenge now is to develop and evaluate systems of care to accurately diagnose patients with severe asthma, assess the multidimensional components of the disease and target treatment accordingly. The National Health and Medical Research Council (NHMRC) Centre of Excellence in Severe Asthma (www.severeasthma.org.au) seeks to develop innovative approaches to understand severe asthma and to address these issues.
As part of the Centre's research and translation agenda, we hosted roundtable discussions focused on severe asthma management with multidisciplinary experts in severe asthma (Table 1) . Discussions were aimed to identifying key knowledge gaps in research and practice, and to develop consensus on areas requiring improvement in severe asthma management. The specific areas were models/systems of care and the implementation of new targeted therapies. This article summarizes these discussions.
To gain a broad insight into current practice in Australia, we designed and disseminated an online survey via SurveyMonkey to clinicians involved in severe asthma management, prior to the roundtable meeting.
The survey was approved by the Hunter New England Human Research Ethics committee and was distributed through mailing lists to severe asthma clinicians. Results from the survey were presented at the roundtable meeting and used to guide discussions; a subset of results are included in this article. The eighty-six survey respondents identified as hospital-based respiratory physicians (43.3%), community-based respiratory physicians (15.6%), other (12.2%) and nurses (7.8%) ( 
SEVERE ASTHMA DEFINITIONS
Severe treatment-refractory asthma (SRA) has been clearly defined and needs to be distinguished from 'Asthma which requires treatment with guidelinesuggested medications corresponding to GINA steps 4-5 asthma (i.e. high-dose inhaled corticosteroids (ICS) and long-acting beta agonists (LABA) or leukotriene modifier/theophylline) for the previous year, or systemic corticosteroids for 50% of the previous year, to prevent symptoms from becoming "uncontrolled", or disease which remains "uncontrolled" despite this therapy'. 6 The survey assessed recognition of SRA, and 82% of respondents agreed that 'severe asthma is likely', when 'asthma symptoms are poorly controlled, despite treatment with ICS/LABA'. A similar proportion responded that severe asthma is likely when (i) 'hospitalization occurs due to asthma symptoms, despite treatment with ICS/LABA' or (ii) 'management requires regular oral corticosteroids (OCSs) use for asthma symptom control'. However, 40% of participants responded that severe asthma is likely when 'non-adherence to ICS and frequent use of short-acting reliever medication occurs'. This indicates that up to 20% of clinicians may not appropriately assign a severe asthma diagnosis and there is still confusion between the definitions of SRA and 'difficult-to-treat asthma'.
These responses prompted discussion on the importance of clear and agreed terminology on the differences between 'undertreated asthma', 'difficult-to-treat asthma' and 'SRA' ( Table 2) . Undertreated asthma is a large problem in countries where access to treatment is limited, but likely to respond well to standard treatment. Hence, access to effective therapy must be distinguished from the problems and solutions for individuals with difficult-to-treat asthma or SRA. Difficult-to-treat asthma is characterized by poorly controlled symptoms and a high risk of exacerbations, despite access to treatment and where symptoms and exacerbations can often be improved by treatment adherence, inhaler technique, reduced trigger exposure and/or treating co-morbidities. Conversely, SRA results in poor symptom control and frequent exacerbations despite good adherence to appropriate treatments. 3 SRA was the primary focus of discussions.
Delegates suggested that the majority of patients with uncontrolled asthma managed in primary care are likely to have difficult-to-treat asthma, with SRA patients mostly managed in tertiary care. Nevertheless, a subgroup of SRA patients still continue to be managed in primary care. Tools to identify and guide the referral of patients with potential SRA are required. Systematic assessment including confirmation of asthma diagnosis, ruling out alternative diagnoses, identification of co-morbidities, assessment of selfmanagement skills and documentation of treatment adherence was deemed critical.
As a result of variability in how definitions are applied, our understanding of SRA prevalence remains poor.
MODELS OF CARE FOR SEVERE ASTHMA MANAGEMENT
Systematic assessment of patients with severe asthma can improve asthma control and health status, and reduce healthcare utilization. 10, 11 However, access to specialist centres that offer this approach is limited, and the most appropriate healthcare model for different settings is unclear.
Current checklists and guidelines
When asked whether standardized checklists for assessment were used, approximately 35% of survey respondents indicated yes, and 77% of these found them useful. Interestingly, 60% of those who did not currently use a checklist believed they would find one useful. Meeting delegates supported standardized checklists, as a means to decrease variability in diagnosis and to guide consistent standards of care. In particular, checklists for diagnosis, referral to specialist care and emergency department discharge were all considered valuable.
When asked about their awareness and the utility of current severe asthma guidelines, a high proportion of respondents were aware of (91%), and referred to (66%), the Australian Asthma Handbook, 12 a guideline that purposely contains very little information about severe asthma. A similar proportion was aware of (87%) and referred to (64%) the ERS/ATS Guidelines on Severe Asthma (Table S2 , Supplementary Information). When asked whether current guidelines for management of severe asthma were useful, only 37% of respondents agreed, although they were considered somewhat useful by 60%. It was proposed that materials specific for SRA should be developed and disseminated to promote consistency of diagnosis and disease management between primary and secondary care.
Diagnosis and assessment
Severe asthma diagnosis is based on a composite of assessments including medical history, physical examination, demonstration of variable airflow limitation and an evaluation of differential diagnoses. 13 A number of recent reviews have highlighted necessary key components and the importance of hierarchical testing in the systematic assessment of disease. 2, 13 Survey respondents were asked about the usage and frequency of testing in diagnosing and assessing SRA. Wide variability was observed (Table S3 , Supplementary Information). While 72% used spirometry at most/all visits, many tests were rarely used. In particular, for measurement of airway inflammation, 53% and 75% never used FeNO or induced sputum, respectively. Meeting delegates highlighted the cost of these investigations, and the lack of MBS reimbursement. Respondents rarely initiated assessments for specific co-morbidities (e.g. naso-endoscopy, functional exercise tests or bone mineral densitometry were never ordered by 60%, 46%, and 32% of respondents, respectively). Similar variability was seen in the use of medical histories and questionnaires (Table S4 , Supplementary Information). Use of questionnaires to assess health status (54%), asthma control (31%) and co-morbidities was limited.
Discussions centred on whether a blanket approach (all assessments applied for all patients) or a bespoke approach (initial screen followed by more intensive assessment guided by initial assessment) should be applied. The consensus was that a bespoke approach is preferred. This overcomes the shortcomings of an unstructured approach, while also optimizing the use of healthcare resources. The practical application of this bespoke strategy is an area of future implementation research.
Patient referral
A recurring theme related to which aspects of diagnosis and disease management should occur in primary care, and when patients should be referred to specialist care (Tables S5,S6 ). Meeting delegates agreed that primary care patients with 'difficult asthma' should be referred. This led to the proposition that specific areas of management be defined within 'levels of care'. For example, in primary care (Level 1), asthma diagnosis should be established and self-management, treatment adherence and co-morbidities optimized. If symptom control cannot be achieved, patients should be referred to specialist care (Level 2). Within specialist care, asthma diagnosis must be reviewed and a systematic assessment performed before SRA is confirmed. Within this setting, it is then possible to escalate therapy, and assess the suitability and efficacy of targeted therapies.
Clear recommendations and guidelines are also required to ensure specialist clinics are not overloaded and can continue to adequately manage patients. The importance of clear, open pathways to return patients back to primary care was established. In the survey, 35% and 38% indicated they referred back 'when disease severity has stabilized and lung function is controlled' or 'when symptoms are absent, lung function is stabilized, rescue medications are no longer required and surveillance is no longer required' (Table S7 , Supplementary Information). A further 11% indicated that they never referred patients back. Discussions recognized that this is not sustainable due to increasing patient numbers and effective treatments, with limited specialist resources. Strategies to guide referral into and out of specialist care are needed.
Multidisciplinary healthcare teams
Assessment and management involving the use of multidisciplinary teams (MDTs) was discussed. Consensus regarding the key team members required for effective management included, at a minimum: an experienced physician, a nurse/case manager and a registrar. The role of allied health members was also discussed. Survey respondents described low involvement by dietitians (34% rarely/17% never) and psychologists (21% rarely/18% never) (Table S8 , Supplementary Information), despite high levels of co-morbid obesity and mental illness in SRA patients. The importance of these health professionals within the severe asthma clinic itself or through referral was advocated. It was noted that there might be potential for better access to psychologists or dietitians within primary care using medicare rebate items.
The importance of MDT members having specific skills and experience necessary for severe asthma management was agreed. As phenotyping and targeted therapy are relatively new, it was acknowledged that there are clear knowledge and training gaps and the need for nursing and allied health training in severe asthma was identified as a priority. Availability of these healthcare professionals embedded in the clinic or through referrals was an attractive option.
Managing co-morbidities
The majority of survey respondents (86%) indicated they manage co-morbidities through referral to specific disciplines (Table S9 , Supplementary Information). Comorbidities are common, 14 and delegates agreed that their management is an important issue. The importance of a person-centred approach to co-morbidity management was recognized, with a need to move away from the current clinician-centred approach where patients are 'siloed' by their co-morbid conditions and see overlapping specialists for each of their co-existing illnesses. The approach used in other conditions such as cystic fibrosis and interstitial lung disease, whereby patients see all relevant specialists on the same day at a multidisciplinary specialist clinic, was suggested as a preferred option. The practicality of this approach would depend on the local healthcare setting and funding.
Adequate access to services
In rural settings, access to adequate staffing and objective testing is often an issue. To attend specialist clinics, patients often travel significant distances, which impacts health status and causes financial burden. The group suggested that rural patients often prefer to remain under the management of a local GP and likely have more limited access to MDT management.
Concern was raised that this may result in lower uptake of treatment; however, insufficient data exist to address this concern. Initiatives were proposed, including training to up-skill healthcare professionals in rural settings, telephone or online support or development of E-Health and TeleHealth approaches. These advances alone, however, might not improve uptake of targeted therapies, which require local access to drugs and specialized services for administration and monitoring.
The impacts of socio-economic status on severe asthma prevalence, recognition and diagnosis, management and access to targeted therapy are unknown. This was raised as an important issue.
IMPLEMENTING NEW THERAPIES INTO SEVERE ASTHMA MANAGEMENT
In a second roundtable meeting, issues relating to current and emerging targeted therapies were discussed. 
Add-on therapies
Survey respondents indicated frequent use of macrolides and monoclonal antibody therapies (Table S10 , Supplementary Information). A high proportion of survey respondents support the cost of treatment through research funding (16%) and clinical trials (20%) (Table S11, Supplementary Information) and therefore this may not be representative of common practice. At the time of the survey, omalizumab was the only government-subsidized biological treatment for SRA in Australia and the Asia-Pacific region, and the numbers of patients treated to date are small. 15 However, with increasing availability of targeted therapies, GPs are increasingly likely to encounter patients prescribed biological therapies. Bronchial thermoplasty was used by 11% of respondents; while this is currently approved, it is not government-funded in Australia.
Discussion followed about how new therapies should be added into existing models of care. It was recognized that there is currently limited information on which patient groups are missing out.
Current approval and monitoring processes
The current Pharmaceutical Benefits Scheme approval process for government-subsidized treatment with new therapies for SRA (e.g. omalizumab) was discussed. Issues were raised about the current process's complexity and whether this is necessary and useful. Consensus was that some of the current complexity is necessary to ensure appropriate diagnosis of SRA, because of the high cost of these medications, and to identify the appropriate patient population. 16 Considered unnecessary, however were, date of diagnosis and requirements/dates for spirometric testing within the preceding 12 months. While it can take several months to optimize inhaled treatment and confirm an SRA diagnosis, the current requirements mandate an automatic 1-year delay in access to treatment. It is proposed that an MDT assessment by expert opinion should be an acceptable alternate approach.
Discussion regarding treatment evaluation for addon and targeted therapies followed, in particular the current approach to determining treatment efficacy. For biological therapies, this generally requires demonstrated improvement in disease-specific outcomes within a 6-month trial period. For omalizumab, continuation of subsidized treatment in Australia requires improved Asthma Control Questionnaire (ACQ) scores or reduction in OCS dose. However, whether these are the optimal outcome measures were debated.
Current barriers to uptake and access
Information on which patient groups are missing out on treatment is limited. Uptake of omalizumab was much lower than initially predicted, 15, 17 suggesting barriers do exist.
A large proportion of survey respondents indicated complexity of the approval process (77%) and drug costs (66%) were barriers to prescribing targeted therapies (Table S12 , Supplementary Information). Patient engagement/adherence (30%), service requirements (30%) and limited local availability/distance to access treatment (28%) were also reported. Limited knowledge/awareness of which patient groups to target with specific therapies was identified by meeting delegates, particularly with the promise of additional new therapies. Without systematic collection of data on these issues, it is difficult to address these factors or to improve access. It was noted that complexity in the approval process likely has larger impacts in the rural settings, where limited resources are available. A larger issue that was raised was that rural patients are often not referred for targeted therapies in the first place.
Funding arrangements
Survey respondents were asked how funding impacts their use of add-on and targeted therapies. The majority of survey respondents (73%) indicated it is a barrier. Further, when specifically asked whether drug expense limited usage, the majority of respondents indicated that cost was a factor (yes 33%/sometimes 56%).
When asked how expensive add-on therapies are currently accessed, survey respondents indicated a mix of sources (Table S13 , Supplementary Information). Pharmaceutical Benefit Scheme funding was utilized by the majority (67%), but alternative mechanisms including hospital funding arrangements (54%) and research/ clinical trials (46%) also represented large proportions. However, these latter sources were identified as unsustainable.
Costs of management and health economics of treatment
Knowledge gaps exist relating to the costs of SRA management and modelling the impact of targeted therapies on healthcare expenses. While there is the perception that targeted therapies are expensive, data from the NHMRC Call for Action suggests that targeted therapy use could reduce healthcare costs. 16 This modelling was based on very conservative estimations of the cost savings of targeted therapies. However, very little information on SRA treatment in Australia or the Asia-Pacific region is available to allow for accurate modelling. Significant knowledge gaps were highlighted, including overall SRA prevalence, phenotype prevalence, rates of phenotype overlap, treatment response, discontinuation rates and expected cost savings resulting from improved health status, decreased disease burden and therapy/ steroid-sparing.
While few targeted approaches are currently approved for SRA treatment, these therapies will increase in the future. As such, economic modelling could predict higher proportions of treatment responsiveness, as more options become available. Since a single initial treatment may not be effective, individual patients will likely need to be trialled on several treatments over time, and to continue long-term therapy on one that is shown to be effective.
Further information is required to inform economic-guided treatment pathways, for example what is the optimal treatment strategy and route at a societal level?
SUMMARY AND FUTURE DIRECTIONS
These roundtable meetings identified a number of key knowledge gaps in severe asthma treatment. From the discussions, recommendations emerged and are detailed in Table 3 . Basic questions remain about the prevalence and burden of disease in Australasia, the impact of clinical setting and the impact of socioeconomic status.
There is little clarity on where diagnosis and management should occur (primary vs tertiary care), recognition and management of co-morbidities and when to refer. Multidisciplinary approaches are important, but the members of these teams are often not funded or available within the clinic. Furthermore, the necessary training and skill sets for team members are not clearly defined or necessarily available.
Whilst add-on and novel targeted therapies can markedly improve patient outcomes, there are a number of barriers to access, including drug costs and approval complexity. The current approval process could be streamlined and optimized. Clear guidelines to inform which therapy to apply to each patient group are needed. Further, cost-effectiveness assessment for new therapies is hindered by limited information on SRA.
CONCLUSIONS
Severe asthma continues to be a problem with ongoing impact on patient outcomes and healthcare systems. With the emergence of novel therapies, there has never been a better time to set a research agenda in severe asthma. This roundtable report highlights knowledge gaps and provides recommendations for future research based on insights from expert clinicians, health policy-makers, professional societies and industry partners.
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